[Adjuvant drug treatment in diabetic patients undergoing percutaneous coronary intervention].
The authors describe the adjuvant drug treatment during and after percutaneous coronary intervention in order to obtain the reduction of major cardiovascular events, focusing in diabetic patients. In the clinical follow-up of diabetic patients after PCI, special attention to the control measures of cardiovascular risk factors should be observed. Among those measures, a normal glycemic level is fundamental, which can be achieved with usual clinical care. Antiplatelet therapy is a controversy issue until know. Although combined antiplatelet therapy with aspirin and a thienopyridynic is well supported by a number of clinical trials, adding GPIIb/IIIa agents as adjuvants in diabetic patients should not be irrestrictive as suggested by some authors; they should be restricted to patients with a significative thrombotic burden.
Lima Filho
Moysés de Oliveira
Mde O
Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, USP, São Paulo, and Laboratório de Hemodinâmica e Cardiologia Intervencionista, Hospital e Maternidade Celso Pierro-PUC, Campinas, SP, Brazil.
Figueiredo
Geraldo Luiz de
GL
Haddad
Jorge Luis
JL
Schmidt
André
A
Lima
Nereida Kilza da Costa
NK
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D001241:Aspirin / Q000627:therapeutic use; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000517:prevention & control / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D023903:Coronary Restenosis / Q000209:etiology* / Q000517:prevention & control; D003331:Coronary Vessels / Q000293:injuries; D048909:Diabetes Complications / Q000517:prevention & control; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D012307:Risk Factors; D015607:Stents
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D001241:Aspirin